NTM lung disease

January 8, 2021January 8, 2021

RHB-204, Oral Treatment for MAC Lung Infections, Put on FDA Fast Track

News

The U.S. Food and Drug Administration (FDA) has given fast track designation to RedHill Biopharma’s RHB-204 as a potential first-line and stand-alone, oral treatment for lung infections caused by Mycobacterium ... Read more

November 23, 2020November 23, 2020

RedHill Launches Trial to Test RHB-204 for Bronchiectasis Plus MAC Lung Infections

News

RedHill Biopharma has launched a Phase 3 clinical trial to evaluate the safety and effectiveness of its investigational oral therapy RHB-204 in adults with bronchiectasis who have lung infections caused ... Read more

October 30, 2020October 30, 2020

Arikayce Approved in Europe for MAC Lung Infections in Non-CF Adults

News

The European Commission has approved Arikayce — liposomal amikacin for inhalation — as the first treatment for lung infections caused by Mycobacterium avium complex (MAC), a type of non-tuberculous mycobacteria ... Read more

August 7, 2020August 7, 2020

CHMP Recommends Arikayce for MAC Lung Infections in Europe

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended Arikayce — liposomal amikacin for inhalation — as a therapy for lung infections caused by Mycobacterium ... Read more

June 1, 2020June 1, 2020

Most Bronchiectasis Patients in Europe Not Tested for NTM Infection as Recommended, Survey Suggests

News

Many bronchiectasis patients in Europe are not being tested for nontuberculous mycobacteria (NTM) infection before starting macrolide antibiotic treatment, as recommended by current guidelines, according to a small survey of physicians ... Read more